Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes StatusStefan D. Anker, Milton Packer, Javed Butler et al.|Circulation|2020Cited by 350
Trends in 30- and 90-Day Readmission Rates for Heart FailureMuhammad Shahzeb Khan, Javed Butler, Jayakumar Sreenivasan et al.|Circulation Heart Failure|2021Cited by 267
Catheter Ablation Versus Medical Therapy for Atrial FibrillationZain Ul Abideen Asad, Stavros Stavrakis, Ali Yousif et al.|Circulation Arrhythmia and Electrophysiology|2019Cited by 222
Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trialJaved Butler, Milton Packer, Ileana L. Piña et al.|European Heart Journal|2020Cited by 179
Ten‐Year Trends in Enrollment of Women and Minorities in Pivotal Trials Supporting Recent US Food and Drug Administration Approval of Novel Cardiometabolic DrugsMuhammad Shahzeb Khan, Erin D. Michos, Izza Shahid et al.|Journal of the American Heart Association|2020Cited by 152